mortality/aging
• most mice die between 12-14 months of age
|
cardiovascular system
• at 6 months, but not 2 months, mice show progressive interstitial/perivascular fibrosis
|
• hearts from 5-month-old mice have a higher number of mitochondria and these mitochondria are smaller than in controls
• however, stroke volume and cardiac output are normal and heart rate is not significantly affected
|
• at 6 months, but not 2 months, hearts show significant cardiac myocyte hypertrophy
|
• by 6 months of age, mice have a 15% increase in heart weight to body weight ratio and a 50% increase by 12 months of age
|
• at 6 months, but not 2 months, hearts show significant cardiac myocyte hypertrophy
• 4-month-old mice show elevated levels of atrial natriuretic factor (ANF), a maker of cardiac hypertrophy
|
• at 6 months, but not 2 months, mice show progressive interstitial/perivascular fibrosis
|
• 12-month-old mice exhibit a 3-fold decline in the maximum rate of change in left ventricular pressure (dp/dt max) and a more than 2.5-fold decline in ejection fraction
• 4-month-old mice exhibit a 2.5-fold decrease in contractility and a significant decrease in ejection fraction
|
• mice show an increase in left ventricular end-diastolic volume and an increase in end-systolic volume, indicating a decline in systolic pressures over time
|
• mice develop progressive cardiomyopathy, showing mild cardiomyopathy as early as 4 months of age
|
• progressive cardiac dysfunction leads to clinical hear failure by 12 months of age
|
growth/size/body
• by 6 months of age, mice have a 15% increase in heart weight to body weight ratio and a 50% increase by 12 months of age
|
• at 6 months, but not 2 months, hearts show significant cardiac myocyte hypertrophy
• 4-month-old mice show elevated levels of atrial natriuretic factor (ANF), a maker of cardiac hypertrophy
|
homeostasis/metabolism
• mice are more sensitive to catecholamine exposure via an acute isoproterenol challenge, showing a greater increase in ejection fraction and dp/dt max; mice show a robust response to isoproterenol and overcome their baseline deficits to eventually reach control levels, however the effect is only transient and cardiac function goes back to baseline within minutes
|
muscle
• at 6 months, but not 2 months, hearts show significant cardiac myocyte hypertrophy
|
• 12-month-old mice exhibit a 3-fold decline in the maximum rate of change in left ventricular pressure (dp/dt max) and a more than 2.5-fold decline in ejection fraction
• 4-month-old mice exhibit a 2.5-fold decrease in contractility and a significant decrease in ejection fraction
|
• mice develop progressive cardiomyopathy, showing mild cardiomyopathy as early as 4 months of age
|
cellular
• at 6 months, but not 2 months, mice show progressive interstitial/perivascular fibrosis
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
cardiomyopathy | DOID:0050700 | J:289614 | ||
congestive heart failure | DOID:6000 | J:289614 |